52 related articles for article (PubMed ID: 38514483)
1. Impact of
Bluemel C; Linke F; Herrmann K; Simunovic I; Eiber M; Kestler C; Buck AK; Schirbel A; Bley TA; Wester HJ; Vergho D; Becker A
EJNMMI Res; 2016 Dec; 6(1):78. PubMed ID: 27785766
[TBL] [Abstract][Full Text] [Related]
2. Long Axial Field-of-View (LAFOV) PET/CT in Prostate Cancer.
Sachpekidis C; Dimitrakopoulou-Strauss A
Semin Nucl Med; 2024 Jun; ():. PubMed ID: 38825439
[TBL] [Abstract][Full Text] [Related]
3. Total Body PET-CT Protocols in Oncology.
Dimitrakopoulou-Strauss A; Pan L; Sachpekidis C
Semin Nucl Med; 2024 Jun; ():. PubMed ID: 38851935
[TBL] [Abstract][Full Text] [Related]
4. Sino-German symposium on total-body PET/CT in theranostics.
Zhang M; Guo R; Wang H; Shi K; Weber WA; Li B
Eur J Nucl Med Mol Imaging; 2024 Jun; ():. PubMed ID: 38837059
[No Abstract] [Full Text] [Related]
5. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
6. The superior detection rate of total-body [
Wang Y; Dong L; Zhao H; Li L; Huang G; Xue W; Liu J; Chen R
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38514483
[TBL] [Abstract][Full Text] [Related]
7. Total-body PET/CT with half-dose [
Liu Y; Li L; Qin Y; Chen Z; Zhao H; Wang X; Chen R
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):581-589. PubMed ID: 37819451
[TBL] [Abstract][Full Text] [Related]
8.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
9. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
10.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
11. Image Quality and Quantitative PET Parameters of Low-Dose [
Calderón E; Schmidt FP; Lan W; Castaneda-Vega S; Brendlin AS; Trautwein NF; Dittmann H; la Fougère C; Kiefer LS
Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892061
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract][Full Text] [Related]
13. Total-body [
Wang Y; Chen Z; Zhu Y; Zhao H; Li L; Huang G; Xue W; Chen R; Liu J
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4096-4106. PubMed ID: 37578502
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
